MX375556B - Compuestos de benzoxaborol tricíclicos y usos de los mismos. - Google Patents

Compuestos de benzoxaborol tricíclicos y usos de los mismos.

Info

Publication number
MX375556B
MX375556B MX2016001732A MX2016001732A MX375556B MX 375556 B MX375556 B MX 375556B MX 2016001732 A MX2016001732 A MX 2016001732A MX 2016001732 A MX2016001732 A MX 2016001732A MX 375556 B MX375556 B MX 375556B
Authority
MX
Mexico
Prior art keywords
sub
compounds
benzoxaborole compounds
tricyclic benzoxaborole
tricyclic
Prior art date
Application number
MX2016001732A
Other languages
English (en)
Other versions
MX2016001732A (es
Inventor
M R K Alley ( Dickon)
David Barros-Aguirre
Ilaria Giordano
Jacob J Plattner
Vincent S Hernandez
Xianfeng Li
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2016001732A publication Critical patent/MX2016001732A/es
Publication of MX375556B publication Critical patent/MX375556B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan compuestos de la fórmula II: (ver Fórmula) en donde X se selecciona a partir de cloro, flúor, bromo y yodo, R1 y R2 se seleccionan cada uno independientemente a partir de H, -CH3, -CH2CH3, -CH2CH2CH3, o -CH(CH3)2,; composiciones que los contienen, su uso en terapia, incluyendo su uso como agentes anti-micobacterianos, por ejemplo, en el tratamiento de una infección micobacteriana en un mamífero, y métodos para la preparación de estos compuestos.
MX2016001732A 2013-08-09 2014-08-08 Compuestos de benzoxaborol tricíclicos y usos de los mismos. MX375556B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864496P 2013-08-09 2013-08-09
US201361918976P 2013-12-20 2013-12-20
PCT/US2014/050370 WO2015021396A2 (en) 2013-08-09 2014-08-08 Tricyclic benzoxaborole compounds and uses thereof

Publications (2)

Publication Number Publication Date
MX2016001732A MX2016001732A (es) 2016-05-18
MX375556B true MX375556B (es) 2025-03-06

Family

ID=52462052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001732A MX375556B (es) 2013-08-09 2014-08-08 Compuestos de benzoxaborol tricíclicos y usos de los mismos.

Country Status (35)

Country Link
US (5) US20160251380A1 (es)
EP (2) EP3030519B1 (es)
JP (2) JP6499175B2 (es)
KR (1) KR102093783B1 (es)
CN (2) CN105492388B (es)
AP (1) AP2016009046A0 (es)
AU (2) AU2014305792C1 (es)
BR (1) BR112016002651B1 (es)
CA (1) CA2919888C (es)
CL (1) CL2016000313A1 (es)
CR (1) CR20160064A (es)
CY (1) CY1125030T1 (es)
DK (1) DK3030519T3 (es)
DO (1) DOP2016000045A (es)
EA (1) EA032844B1 (es)
ES (1) ES2905413T3 (es)
HR (1) HRP20220384T1 (es)
HU (1) HUE057365T2 (es)
IL (1) IL243874B (es)
LT (1) LT3030519T (es)
MX (1) MX375556B (es)
MY (1) MY175823A (es)
NZ (1) NZ716350A (es)
PE (1) PE20160752A1 (es)
PH (1) PH12016500234B1 (es)
PL (1) PL3030519T3 (es)
PT (1) PT3030519T (es)
RS (1) RS62887B1 (es)
SA (1) SA516370551B1 (es)
SG (2) SG10201914073PA (es)
SI (1) SI3030519T1 (es)
SM (1) SMT202200113T1 (es)
UA (1) UA116908C2 (es)
WO (1) WO2015021396A2 (es)
ZA (1) ZA201600792B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094961A1 (es) * 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
CN106459097A (zh) 2014-07-01 2017-02-22 第三共株式会社 作为抗菌剂的三环苯并氧杂硼杂环戊烯类
MA41495A (fr) * 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
PE20190119A1 (es) 2016-05-12 2019-01-17 Anacor Pharmaceuticals Inc Esteres de oxaborol y sus usos
CN109387594B (zh) * 2017-08-08 2021-01-19 武汉武药科技有限公司 一种分离和分析贝达喹啉光学异构体的方法
ES2949908T3 (es) * 2018-01-09 2023-10-03 Halcyon Labs Private Ltd Proceso para la preparación de Crisaborol y sus intermedios
EP4164645A4 (en) * 2020-06-15 2024-07-10 The Global Alliance for TB Drug Development, Inc. COMBINED ANTIBACTERIAL COMPOSITION AND ANTIBACTERIAL THERAPY METHOD
CN111606850B (zh) * 2020-07-07 2023-07-25 安徽贝克生物制药有限公司 贝达喹啉及其中间体的制备方法
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CA3239097A1 (en) 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Prodrugs of boron compounds and their use in treating bacterial infections
JP2025520237A (ja) * 2022-06-23 2025-07-03 ミクウルク ファーマシューティカルズ, インコーポレイテッド ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
WO2024208907A1 (en) 2023-04-05 2024-10-10 Glaxosmithkline Intellectual Property (No. 2) Limited Synthesis of 3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3h)-ol
CN117379430B (zh) * 2023-10-11 2026-07-21 深圳市第三人民医院(深圳市肝病研究所) 一种地拉韦啶的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024753A1 (en) 1996-12-02 1998-06-11 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
CN101505603A (zh) * 2005-12-30 2009-08-12 安纳考尔医药公司 含硼的小分子
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
SG172040A1 (en) 2008-12-17 2011-07-28 Anacor Pharmaceuticals Inc Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
AU2011237681B2 (en) * 2010-04-07 2015-01-22 Glaxosmithkline Llc Process for preparing benzoxaboroles
DK2613788T3 (en) * 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
US8530452B2 (en) * 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
MA41495A (fr) * 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations

Also Published As

Publication number Publication date
RS62887B1 (sr) 2022-03-31
SA516370551B1 (ar) 2017-10-31
US20160251380A1 (en) 2016-09-01
CN110003253A (zh) 2019-07-12
CN105492388B (zh) 2018-12-21
AU2014305792A1 (en) 2016-03-10
WO2015021396A2 (en) 2015-02-12
CN110003253B (zh) 2022-03-18
PE20160752A1 (es) 2016-08-17
SG11201600787PA (en) 2016-03-30
AP2016009046A0 (en) 2016-02-29
US20210053999A1 (en) 2021-02-25
HK1219939A1 (zh) 2017-04-21
ES2905413T3 (es) 2022-04-08
JP6764970B2 (ja) 2020-10-07
US20200095266A1 (en) 2020-03-26
PT3030519T (pt) 2022-01-27
DK3030519T3 (da) 2022-01-31
EP3030519A2 (en) 2016-06-15
CN105492388A (zh) 2016-04-13
DOP2016000045A (es) 2016-04-29
SI3030519T1 (sl) 2022-04-29
CL2016000313A1 (es) 2016-09-23
HUE057365T2 (hu) 2022-05-28
JP2019123727A (ja) 2019-07-25
CA2919888C (en) 2022-10-18
US10858376B2 (en) 2020-12-08
AU2017210567B2 (en) 2019-08-01
KR102093783B1 (ko) 2020-03-26
AU2014305792B2 (en) 2017-05-04
HRP20220384T1 (hr) 2022-07-22
AU2014305792C1 (en) 2018-07-05
US20180044355A1 (en) 2018-02-15
SG10201914073PA (en) 2020-03-30
WO2015021396A9 (en) 2016-02-11
PH12016500234B1 (en) 2019-01-30
KR20160038901A (ko) 2016-04-07
CR20160064A (es) 2016-06-01
PL3030519T3 (pl) 2022-05-23
WO2015021396A3 (en) 2015-10-29
US20190241586A1 (en) 2019-08-08
IL243874B (en) 2018-11-29
JP2016527321A (ja) 2016-09-08
IL243874A0 (en) 2016-04-21
UA116908C2 (uk) 2018-05-25
US10308668B2 (en) 2019-06-04
BR112016002651B1 (pt) 2022-11-29
NZ716350A (en) 2022-12-23
MX2016001732A (es) 2016-05-18
EP3030519A4 (en) 2017-03-08
US10526352B2 (en) 2020-01-07
EP3030519B1 (en) 2022-01-05
PH12016500234A1 (en) 2016-05-16
ZA201600792B (en) 2022-05-25
EA032844B1 (ru) 2019-07-31
MY175823A (en) 2020-07-10
EP4029870A1 (en) 2022-07-20
CA2919888A1 (en) 2015-02-12
JP6499175B2 (ja) 2019-04-10
LT3030519T (lt) 2022-04-11
SMT202200113T1 (it) 2022-05-12
EA201690135A1 (ru) 2016-07-29
BR112016002651A2 (pt) 2017-08-01
CY1125030T1 (el) 2023-03-24
AU2017210567A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
WO2015021396A3 (en) Tricyclic benzoxaborole compounds and uses thereof
PH12017501427A1 (en) Benzoxaborole compounds and uses thereof
EA201891861A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
PH12016500643B1 (en) NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c'] DIPYRROL-2-YL
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
MA40281A (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
TW201613864A (en) Novel compounds
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
EA201600434A1 (ru) Применение производных бензимидазолпролина
PH12018500377A1 (en) Novel annelated benzamides
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MX378932B (es) Triazoles sustituidos y métodos relacionados a estos.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
GEAP201814272A (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
JO3673B1 (ar) مكونات البنزوكسابورول ثلاثي الحلقات واستخداماتها
EA201990934A1 (ru) Трициклические соединения бензоксаборола и их применение

Legal Events

Date Code Title Description
FG Grant or registration